Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The company's lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata, as well as a Phase 2 trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3] Upcoming Events - Nektar Therapeutics will participate in the Jefferies Global Healthcare Conference from November 17-20, 2025, in London, with a webcast scheduled for November 20, 2025, at 11:00 a.m. GMT / 3:00 a.m. PT [1] - A replay of the presentation will be available for 30 days following the event [1] Financial Information - The company is set to announce its financial results for the third quarter on November 6, 2025, after the close of U.S.-based financial markets [5]

Core Insights - Nektar Therapeutics will announce its third-quarter financial results on November 6, 2025, after U.S. market close, with a conference call hosted by CEO Howard Robin at 5:00 p.m. Eastern Time [1] - The conference call will be accessible via a link on Nektar's website, with a replay available until December 6, 2025 [2] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata, as well as a Phase 2 trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent TNFR2 antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified CSF protein NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3]